Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs McKesson Corporation — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $27.7, while McKesson Corporation trades at $829.3 (market cap $97.35B). The key difference: McKesson Corporation pays a 0.39% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none, and McKesson Corporation is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| KOLD | MCK | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $995.69 |
52-Week Low | $13.58 | $659.01 |
Market Cap | — | $97.35B |
Enterprise Value | — | $101.98B |
Dividend Yield | — | 0.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD trades at $28.25, up 4.01% today, with a bullish technical signal from moving averages and strong trend strength indicated by ADX. Recent news highlights natural gas market volatility driven by weather forecasts and storage reports, with the ETF positioned as a tactical trading tool amid price swings around $3/MMBtu (Seeking Alpha, 2026-06-08).
The outlook remains tied to natural gas price movements, with opportunities for short-term gains from volatility but risks from weather-dependent demand shifts and production levels. Investors face commodity price exposure and leverage risks inherent in inverse ETFs.
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
